Research programme: human cytomegalovirus primase inhibitors - Amgen

Drug Profile

Research programme: human cytomegalovirus primase inhibitors - Amgen

Alternative Names: Human cytomegalovirus primase inhibitors research programme - Amgen; T 0902395

Latest Information Update: 09 Dec 2003

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Tularik
  • Class
  • Mechanism of Action Cytomegalovirus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Cytomegalovirus infections

Most Recent Events

  • 09 Dec 2003 Discontinued - Preclinical for Cytomegalovirus infections treatment in USA (unspecified route)
  • 29 Jan 2002 Preclinical development for Cytomegalovirus infections in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top